Detalhe da pesquisa
1.
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.
Invest New Drugs
; 40(4): 789-797, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477812
2.
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
BMC Cancer
; 22(1): 55, 2022 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35016637
3.
Emerging roles of epithelial-mesenchymal transition in hematological malignancies.
J Biomed Sci
; 25(1): 37, 2018 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29685144
4.
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.
Oncologist
; 21(5): 537-8, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091418
5.
Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan.
Gastric Cancer
; 19(2): 490-497, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25772342
6.
Risk of cancer in children, adolescents, and young adults with autistic disorder.
J Pediatr
; 166(2): 418-23.e1, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25453246
7.
The association between prostate cancer and mood disorders: a nationwide population-based study in Taiwan.
Int Psychogeriatr
; 27(3): 481-90, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25335499
8.
External beam radiation therapy with or without concurrent chemotherapy for patients with unresectable locally advanced hilar cholangiocarcinoma.
Hepatogastroenterology
; 62(137): 102-7, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25911877
9.
Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
Am J Gastroenterol
; 112(4): 659-660, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28381841
10.
Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report.
Medicine (Baltimore)
; 101(39): e30719, 2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36181052
11.
Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review.
Front Immunol
; 13: 994064, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36119082
12.
Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance.
Cells
; 11(4)2022 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35203285
13.
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma.
Ther Adv Med Oncol
; 14: 17588359221099401, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35646162
14.
Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 14(8)2022 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35454919
15.
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Hepatol Int
; 16(5): 1199-1207, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986846
16.
A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma.
Clin Cancer Res
; 28(23): 5058-5065, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36129471
17.
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.
Clin Cancer Res
; 28(19): 4248-4257, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35849151
18.
Is 1-year follow-up adequate for adult tuberculosis contacts?
Eur Respir J
; 45(5): 1501-4, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25700384
19.
Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 12(1)2020 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31940757
20.
Expression profiledriven discovery of AURKA as a treatment target for liposarcoma.
Int J Oncol
; 55(4): 938-948, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31485600